Foxp3-positive cells were significantly decreased in both EAN groups treated with VIP, and serum concentrations of IL-17 and IFN- were significantly lower compared with the untreated EAN group ( em P /em 0
Foxp3-positive cells were significantly decreased in both EAN groups treated with VIP, and serum concentrations of IL-17 and IFN- were significantly lower compared with the untreated EAN group ( em P /em 0.05). Conclusion In a rat model of EAN, treatment with VIP resulted in functional improvement, reduced nerve inflammation, and decreased serum levels of inflammatory cytokines. strong class="kwd-title" Keywords: Guillain, Barr syndrome, vasoactive intestinal peptide, experimental autoimmune neuritis, acute inflammatory demyelinating polyradiculoneuropathy Introduction Worldwide, GuillainCBarr syndrome (GBS), also known as acute inflammatory demyelinating polyradiculoneuropathy, is a neurological condition that can occur in otherwise healthy adults and at any age, with a reported incidence of 1C4 per 100,000 individuals.1,2 VTP-27999 Owing to the improvements in the diagnosis of GBS, the disease has been shown to have an increasing incidence rate.3,4…